Ann: Quarterly Cashflow Report - June 2023, page-148

First 148 Last

Share
Profile

Follow
Simoncho

5,410 Posts.

542

06/08/23

22:12

Post #: 69189328
Share

Originally posted by elpassive: ↑

Yea I was gonna say if they gave loan to Puna for $6.4M, you would expect Puna to use that capital to ramp the capacity of carbonate production.They would not use all of that up in a quarter. You also can't rush the battery testing qualification of the sample products supplied to customers. There is a lag there as they want to make sure that it reach to their rigious specifications.

Once they announce offtake partner, it would be easier to raise more capital as the share price would appreciate and not dilute existing shareholders. So I don't get why people are scared lol, there is literally not a lot of companies at the same stage as Argosy.

My only issue and this to me is the only valid criticism is the cost of production at scale. There will be a cost that becomes uneconomic to operate if the spot price is indexed to the chinese market. The chinese spot price has a lot of manipulation. I really hope the material is sold to North America where you avoid those funky games. Even Japan and Korea is quite good to sell lithium because their LCE pricing is on the high end.

I am betting Eric Norris from Albermarle is correct and we have high prices for longer, since every other deposit besides Atacama (brines) and greenbushes (hard rock) sit on the right hand side of the cost curve. That cost is around $25K a tonne (ball park) so the price of LCE has to be higher than that for longer. Otherwise Argosy would start and stop production which is the sensible thing to do but operationally is a nightmare.

I bought more as for $300M market cap you are getting not a lot of risk but high long terms rewards.

Expand

JZ is using North Asia pricing as reference for the offtake terms, so a Japanese or Korean partner seems likely. LG Chem would be awesome.

AGY Price at posting: 31.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

RXL

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 22 more messages in this thread...

First 148 Last

Add AGY (ASX) to my watchlist

(20min delay)
Last 4.0¢		Change 0.002(5.26%)		Mkt cap ! $55.32M

Open	High	Low	Value	Volume
3.9¢	4.0¢	3.9¢	$106.7K	2.736M

Buyers (Bids)

No.	Vol.	Price($)
2	179032	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	1079381	9

View Market Depth

No.	Vol.	Price($)
1	117205	0.039
5	380000	0.038
6	795581	0.037
23	2482708	0.036
27	2679749	0.035

Price($)	Vol.	No.
0.040	1109381	10
0.041	700856	8
0.042	1035817	10
0.043	1582232	4
0.044	1316726	8

Last trade - 10.34am 04/10/2024 (20 minute delay)

AGY (ASX) Chart

Ann: Quarterly Cashflow Report - June 2023, page-148

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Cashflow Report - June 2023, page-148

Top Stories

Diamond drilling hits gold at 16.71 g/t for Rox at Paddy's Lode, extending mineralisation

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News